T1	Procedure 0 12	immunization
T2	Drug 18 23	PPV23
T3	Temporal 24 44	within the last year
R1	AND Arg1:T1 Arg2:T2	
T4	Condition 73 99	immunodeficiency condition
T5	Qualifier 63 72	suspected
T6	Qualifier 50 59	confirmed
T7	Condition 111 139;146 155	human immunodeficiency virus infection
T8	Condition 141 144	HIV
R2	Subsumes Arg1:T7 Arg2:T8	
T9	Condition 157 182	haematological malignancy
T10	Condition 189 216	congenital immunodeficiency
*	OR T9 T10 T7
T11	Scope 111 216	human immunodeficiency virus (HIV) infection, haematological malignancy, or a congenital immunodeficiency
R3	Subsumes Arg1:T4 Arg2:T11	
T12	Scope 50 72	confirmed or suspected
R4	Has_scope Arg1:T4 Arg2:T12	
T13	Condition 229 245	allergic disease
T14	Condition 229 237;249 258	allergic reactions
*	OR T13 T14
T15	Scope 229 258	allergic disease or reactions
T16	Qualifier 272 315	exacerbated by any component of the vaccine
T17	Procedure 308 315	vaccine
R5	multi Arg1:T16 Arg2:T17	
R6	Has_qualifier Arg1:T15 Arg2:T16	
T18	Condition 328 344	allergic disease
T19	Qualifier 358 387	stimulated by the vaccination
T20	Procedure 376 387	vaccination
R7	multi Arg1:T19 Arg2:T20	
R8	Has_qualifier Arg1:T18 Arg2:T19	
T21	Procedure 411 436	immunosuppressive therapy
T22	Procedure 460 483	topical corticosteroids
T23	Negation 447 456	exception
R9	Has_negation Arg1:T22 Arg2:T23	
T24	Temporal 485 506;527 541	for more than 14 days of vaccination
T25	Temporal 511 541	within 6 months of vaccination
T26	Scope 485 541	for more than 14 days and within 6 months of vaccination
R10	Has_scope Arg1:T21 Arg2:T26	
T27	Reference_point 530 541	vaccination
R11	Has_index Arg1:T25 Arg2:T27	
R12	Has_index Arg1:T24 Arg2:T27	
R13	Has_scope Arg1:T22 Arg2:T26	
T28	Procedure 584 599	immunoglobulins
T29	Procedure 611 625	blood products
T30	Temporal 626 649	during the study period
T31	Temporal 653 704	within the three months preceding the study vaccine
T32	Reference_point 637 649	study period
T33	Reference_point 691 704	study vaccine
R14	Has_index Arg1:T30 Arg2:T32	
R15	Has_index Arg1:T31 Arg2:T33	
*	OR T30 T31
*	OR T28 T29
T34	Grammar_Error 600 606	and/or
T35	Scope 584 625	immunoglobulins and/or any blood products
T36	Scope 626 704	during the study period or within the three months preceding the study vaccine
R16	Has_scope Arg1:T35 Arg2:T36	
T37	Procedure 765 772	vaccine
T38	Procedure 757 761	drug
T39	Qualifier 723 738	investigational
T40	Qualifier 742 756	non-registered
*	OR T39 T40
*	OR T38 T37
T41	Scope 757 772	drug or vaccine
T42	Scope 723 756	investigational or non-registered
R17	Has_scope Arg1:T41 Arg2:T42	
T43	Temporal 773 796	during the study period
T44	Temporal 800 842	within 30 days preceding the study vaccine
T45	Reference_point 784 796	study period
T46	Reference_point 829 842	study vaccine
R18	Has_index Arg1:T43 Arg2:T45	
R19	Has_index Arg1:T44 Arg2:T46	
*	OR T43 T44
T47	Scope 773 842	during the study period or within 30 days preceding the study vaccine
R20	Has_scope Arg1:T41 Arg2:T47	
T48	Procedure 864 871	vaccine
T49	Temporal 872 962	during the period starting one month before the dose of vaccine and ending one month after
T51	Reference_point 916 935	the dose of vaccine
T52	Procedure 928 935	vaccine
R21	Has_index Arg1:T49 Arg2:T51	
R22	multi Arg1:T51 Arg2:T52	
T50	Condition 964 973	pregnancy
